Atlas Trials

Clinical Outcomes of 3L+ Therapies Among Patients With Chronic Myeloid Leukemia and Those With T315I Mutation

Clinical trial NCT05611216 · COMPLETED

Trial details

NCT number
NCT05611216
Sponsor
Novartis Pharmaceuticals
Status
COMPLETED
Study type
OBSERVATIONAL
Chronic Myeloid Leukemia
Start date
2020-12-01
Primary completion
2021-12-23
Enrollment
164

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.